Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 11

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 11
---
. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words including, but not limited to, “anticipate,” “believe,” “contemplates,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “likely,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will,” “would,” “seek,” “should,” “target,” or the negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. These factors include those described in Part I, Item 1A-Risk Factors” in our 2024 Annual Report. Meaningful factors that could cause actual results to differ from those expressed in forward-looking statements include, but are not limited to:

| • | Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future 
 product candidates;                                                                                                                                                                                                                          |

| • | The regulatory approval processes of the U.S. Food and Drug Administration (“FDA”) and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval 
 for our product candidates, our business will be materially harmed;                                                                                                                                                                           |

| • | Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a 
 timely basis or at all;                                                                                                                                                                                                                    |

| • | Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is 
 completed or in later stage trials;                                                                                                                                                                                                   |

| • | The scope, progress and costs of developing our product candidates such as EB613 for osteoporosis and EB612 or other oral peptides for hypoparathyroidism may alter over time based on various factors such as regulatory requirements, 
 collaboration agreements, the competitive environment and new data from pre-clinical and clinical studies;                                                                                                                              |

| • | The accuracy of our estimates regarding expenses, capital requirements, the sufficiency of our cash resources and the need for additional financing; |

| • | Our ability to continue as a going